
    
      The study is an open-label, prospective, multicenter, post-CE mark (European Conformity
      assessment indicating marketing approval in Europe) study to assess the safety and
      performance of the VistaCareÂ® device in the treatment of wounds. The duration of patient
      follow-up is up to 30 days, with intermediate visits at 3, 7, 15 and 30 days following
      initiation of treatment with the device.

      Up to 30 patients will be recruited in the trial. Assessments will include clinical status,
      wound status, standardized photography, TcPO2 (trans-cutaneous oxygen pressure assessment) in
      a study sub-population, visual analogy scales to assess pain and comfort and adverse events
      monitoring.
    
  